Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NASAREL vs VANCENASE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Corticosteroid that binds to glucocorticoid receptors, inhibiting inflammatory mediators such as prostaglandins, leukotrienes, and cytokines, thereby reducing nasal inflammation.
Beclomethasone dipropionate is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to glucocorticoid receptors, leading to inhibition of inflammatory mediators such as cytokines and prostaglandins.
Seasonal and perennial allergic rhinitis,Nonallergic rhinitis,Nasal polyps (off-label)
Treatment of allergic rhinitis (seasonal and perennial),Management of nonallergic rhinitis,Prevention of recurrence of nasal polyps after polypectomy
2 sprays (50 mcg/spray) in each nostril once or twice daily; maximum 8 sprays/day.
1-2 inhalations (50-100 mcg) per nostril twice daily (100-200 mcg/day total).
Terminal half-life approximately 15-25 minutes for flunisolide (the active ingredient in NASAREL) in the systemic circulation after intranasal administration. Clinically, the half-life is short, reducing the risk of systemic accumulation but requiring twice-daily dosing for consistent effect.
Terminal elimination half-life is approximately 3.5 hours after intranasal administration. Clinically, this short half-life supports twice-daily dosing for sustained effect.
Primarily hepatic via CYP3A4 isoform; undergoes extensive first-pass metabolism.
Hepatic via cytochrome P450 3A4 (CYP3A4) to active metabolite beclomethasone-17-monopropionate, which is further metabolized.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <30% of dose. Fecal elimination minimal (<5%).
Primarily hepatic metabolism; excreted in urine (approximately 10% as unchanged drug and metabolites) and feces (approximately 80% as metabolites).
Approximately 40-50% bound to plasma proteins, primarily albumin.
Approximately 87% bound to plasma proteins, primarily albumin.
Volume of distribution is approximately 1.4–2.0 L/kg after IV administration, indicating extensive tissue distribution. For intranasal use, the Vd is not directly applicable but reflects systemic exposure if absorbed.
Volume of distribution is approximately 2.6 L/kg, indicating extensive tissue distribution.
Intranasal: Systemic bioavailability is approximately 21% (range 10-50%) due to first-pass metabolism. Oral bioavailability is <1% due to extensive hepatic first-pass effect. The drug is administered intranasally for local effect with low systemic exposure.
Intranasal: approximately 50% systemic bioavailability due to direct absorption across nasal mucosa and some gastrointestinal absorption from swallowed portion. Oral: low and variable (approximately 20%) due to first-pass metabolism.
No dose adjustment required for renal impairment.
No adjustment required for renal impairment.
No dose adjustment required for hepatic impairment.
No adjustment required for hepatic impairment.
Children 6-11 years: 1 spray in each nostril once daily; maximum 4 sprays/day. Children ≥12 years: same as adult.
Age 6-11 years: 1 inhalation (50 mcg) per nostril once daily, may increase to twice daily if needed. Age 12-17 years: same as adult.
No specific dose adjustment; use lowest effective dose.
No specific dose adjustment; use lowest effective dose due to potential increased sensitivity.
None
None
May cause epistaxis, nasal septal perforation, or nasal mucosal ulceration,Potential for systemic corticosteroid effects with prolonged use,May suppress hypothalamic-pituitary-adrenal (HPA) axis, especially at higher doses,Increased susceptibility to infections; avoid in active untreated infections,Use with caution in patients with tuberculosis, ocular herpes simplex, or untreated fungal/bacterial infections
Nasal irritation, epistaxis, and nasal septal perforation,Potential for systemic corticosteroid effects with prolonged use (e.g., adrenal suppression, growth retardation in children),Avoid use in patients with active or quiescent tuberculosis, untreated fungal, bacterial, or viral infections,Use with caution in patients with recent nasal surgery or trauma
Hypersensitivity to flunisolide or any component of the formulation,Untreated localized nasal infections (e.g., bacterial, fungal, viral)
Hypersensitivity to beclomethasone or any component of the formulation,Status asthmaticus or other acute episodes of asthma
No significant food interactions known. May take without regard to meals. Avoid consuming grapefruit or grapefruit juice as it may increase systemic exposure (weak CYP3A4 interaction).
No significant food interactions. Grapefruit and grapefruit juice do not interact with intranasal beclomethasone. Avoid alcohol if it exacerbates nasal congestion.
FDA Pregnancy Category C: In animal studies, corticosteroids have been shown to be teratogenic at high doses. No adequate and well-controlled studies in pregnant women. Nasarel (flunisolide) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. First trimester: Theoretical risk of cleft palate; avoid systemic absorption by using minimal effective dose. Second and third trimesters: No specific risks reported; monitor for fetal adrenal suppression if used chronically at high doses.
VANCENASE (beclomethasone dipropionate) is an inhaled corticosteroid. In animal studies, corticosteroids have been shown to be teratogenic. However, inhaled corticosteroids at recommended doses are not associated with a significant increase in congenital malformations. First trimester: Limited data, but no clear evidence of increased risk. Second and third trimesters: Risk of intrauterine growth restriction (IUGR) with prolonged high-dose systemic exposure; inhaled doses minimize systemic absorption.
It is not known whether flunisolide is excreted in human milk. Because many corticosteroids are excreted in human milk, caution should be exercised when Nasarel is administered to a nursing woman. M/P ratio not available. Use with caution; consider using lowest effective dose and monitoring infant for signs of adrenal suppression.
Beclomethasone is excreted in breast milk in small amounts. Inhaled corticosteroids at therapeutic doses are considered compatible with breastfeeding. The milk-to-plasma ratio is not well established for beclomethasone; assume low due to extensive first-pass metabolism. Risks to infant are negligible at maternal inhaled doses.
No specific dose adjustments required due to pharmacokinetic changes in pregnancy. Use lowest effective dose to minimize systemic absorption. No change in hepatic metabolism or renal clearance expected for intranasal flunisolide.
No routine dose adjustment required for beclomethasone dipropionate during pregnancy. Pharmacokinetic changes (increased clearance, decreased plasma protein binding) may theoretically reduce systemic exposure, but inhaled doses are titrated to clinical response. Use lowest effective dose to maintain asthma control.
For best results, advise patients to blow nose gently before use. Avoid spraying directly onto nasal septum to reduce risk of epistaxis and septal perforation. Tilt head forward slightly and spray away from septum. Priming pump (6 sprays or until fine mist appears) is essential if not used for >7 days. Monitor nasal mucosal integrity during long-term use. May cause transient stinging or burning; consider co-administration with saline spray if irritation persists.
VANCENASE (beclomethasone dipropionate) is an intranasal corticosteroid. Onset of action is not immediate; regular use for several days to weeks is needed for full effect. Priming with 6-7 sprays after prolonged non-use is required. Shake well before use. Avoid spraying directly onto the nasal septum to prevent irritation and bleeding. May cause epistaxis and nasal septal perforation with long-term use. Monitor for signs of adrenal suppression when used at higher than recommended doses.
Use exactly as prescribed; do not exceed recommended dose.,Shake bottle gently before each use.,Prime pump by spraying 6 times into air if new or not used for 7 or more days.,Blow nose to clear nasal passages before administration.,Insert nozzle into nostril, tilt head slightly forward, and spray away from the nasal septum.,Avoid spraying directly onto the nasal septum.,Rinse nozzle with warm water after each use and replace cap tightly.,Do not share the medication with others.,If using other nasal sprays, use them at different times (separated by 10-15 minutes).,Contact doctor if symptoms do not improve after 3 weeks or if nasal bleeding occurs.
Use regularly as prescribed, not for immediate relief.,Shake the canister gently before each use.,Prime the pump by spraying 6-7 times into the air if not used for more than 1 week.,Blow nose gently before each use to clear nasal passages.,Insert nozzle into nostril, aim away from septum, and spray while breathing gently.,Do not use more than 2 sprays per nostril daily.,Rinse nozzle with warm water and dry after each use to prevent clogging.,Report persistent nosebleeds, severe nasal irritation, or signs of infection.,Do not stop abruptly; taper as directed.,Keep out of reach of children.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NASAREL vs VANCENASE, answered by our medical review team.
NASAREL is a Intranasal Corticosteroid that works by Corticosteroid that binds to glucocorticoid receptors, inhibiting inflammatory mediators such as prostaglandins, leukotrienes, and cytokines, thereby reducing nasal inflammation.. VANCENASE is a Intranasal Corticosteroid that works by Beclomethasone dipropionate is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to glucocorticoid receptors, leading to inhibition of inflammatory mediators such as cytokines and prostaglandins.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NASAREL and VANCENASE depend on the specific clinical indication. These are both Intranasal Corticosteroid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NASAREL is: 2 sprays (50 mcg/spray) in each nostril once or twice daily; maximum 8 sprays/day.. The standard adult dose of VANCENASE is: 1-2 inhalations (50-100 mcg) per nostril twice daily (100-200 mcg/day total).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NASAREL and VANCENASE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NASAREL is classified as Category C. FDA Pregnancy Category C: In animal studies, corticosteroids have been shown to be teratogenic at high doses. No adequate and well-controlled studies in pregnant women. Nasarel (fl. VANCENASE is classified as Category C. VANCENASE (beclomethasone dipropionate) is an inhaled corticosteroid. In animal studies, corticosteroids have been shown to be teratogenic. However, inhaled corticosteroids at reco. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.